TransMedics Group, Inc. $TMDX Position Increased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 54.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,125 shares of the company’s stock after purchasing an additional 109,830 shares during the quarter. ArrowMark Colorado Holdings LLC owned approximately 0.92% of TransMedics Group worth $35,133,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TMDX. Marshall Wace LLP increased its position in TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after buying an additional 394,340 shares during the period. Two Sigma Investments LP boosted its holdings in shares of TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares during the period. Zevenbergen Capital Investments LLC boosted its holdings in shares of TransMedics Group by 112.7% during the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after acquiring an additional 136,995 shares during the period. Next Century Growth Investors LLC bought a new position in shares of TransMedics Group during the second quarter worth about $16,049,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other TransMedics Group news, CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the sale, the chief financial officer directly owned 14,689 shares in the company, valued at approximately $2,162,367.69. The trade was a 33.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the sale, the director directly owned 2,866 shares of the company’s stock, valued at approximately $428,810.92. This represents a 29.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $123.48 on Friday. TransMedics Group, Inc. has a one year low of $62.23 and a one year high of $156.00. The stock’s fifty day moving average is $135.92 and its 200-day moving average is $127.27. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. The firm has a market capitalization of $4.24 billion, a price-to-earnings ratio of 25.20 and a beta of 1.98.

Analyst Ratings Changes

Several brokerages recently weighed in on TMDX. Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research report on Monday, March 9th. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Oppenheimer raised their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group lifted their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Needham & Company LLC boosted their price objective on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $152.33.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.